Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases. Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures. Click here to get in touch with our team.
NeoVentures was formed as an aptamer development company in June of 2002, and founded on a very simple principle. Businesses that create real sustainable value for their clients succeed. This does not always seem to be case as we have all seen biotechnology companies that… Read More »Why has NeoVentures succeeded as an Aptamer development company?
NeoVentures is the leader for aptamer development globally because we have led and are continuing to lead with improvements to the aptamer development process. Over the past two years, we have reinvented aptamer development because this was needed. Aptamers for Diagnostics and Therapeutics Clients using… Read More »Why Should NeoVentures Develop Your Aptamers?
We recently asked which of the following applications cannot be done with aptamers? The results were overwhelmingly in favor of one choice: We can go through each option to see how aptamers are indeed able to be used in diagnostics, therapeutics, and drug discovery but… Read More »What Cannot Be Done with Aptamers?
NeoVentures is pleased to announce that a long term project with a Fortune 500 company regarding the development of an aptamer that binds to a transmembrane receptor is currently under review by the FDA. This multi-year project was contracted to NeoVentures because of our expertise… Read More »Aptamers That Bind to a Transmembrane Receptor
NeoVentures is pleased to announce the successful completion of a project with a Fortune 500 pharmaceutical company resulting in the development of aptamers as tools for high throughput biomanufacturing of drugs. The key advantage of aptamers in this type of application is the capacity to… Read More »Aptamers for Biomanufacturing of Drugs
In our “What is an aptamer” blog, we described that aptamers are synthetically made, single-stranded DNA or RNA molecules. There are inherent differences between DNA and RNA when found naturally. DNA is typically a double-stranded biomolecule composed of A, T, C, and G bases. RNA… Read More »DNA vs RNA Aptamers
Currently, at NeoVentures, we believe that there is no concrete answer to the question if aptamers are better than antibodies. We have thoughts on why aptamers would be more useful in specific cases, but there just isn’t the same amount of literature available yet on… Read More »Are Aptamers Better than Antibodies?
Aptamers are selected from large libraries of random sequences, thus aptamers themselves are not designed but the libraries that they are selected from are. The standard method of aptamer design has been for SELEX selection. This involves a synthetic library with a random region flanked… Read More »Aptamer Libraries – What is Neomers?
We thought that the World Cup was a timely icon for this blog series. This will be a blog series because there are so many reasons why we are the best aptamer company. What are they? You own the aptamers, no royalties. Innovative NEOMER aptamer… Read More »Why is NeoVentures the Best Aptamer Company for Your Needs?
What determines the binding capacity of an aptamer? Our poll results indicate that……… Nature of the target The peptide bond Nucleotide staking free energy Van der Waals forces Let’s go through the options one by one to determine the correct answer. b) The Peptide Bond. It… Read More »What Determines the Binding Capacity of an Aptamer?
Subscribe to be the first to know about the latest developments and innovations in commercial aptamers